Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer maintains a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $150 to $220.
July 22, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained a Neutral rating on Alnylam Pharmaceuticals but raised the price target from $150 to $220, indicating a positive outlook despite the neutral stance.
The increase in the price target from $150 to $220 suggests that the analyst sees potential for growth in Alnylam Pharmaceuticals' stock price. However, the Neutral rating indicates that the analyst believes the stock is fairly valued at its current price. This mixed signal could lead to a modest positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100